First-in-human trial shows promising results for antibody-drug conjugate in relapsed small cell lung cancer
A first-in-human Phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and